Fig. 3: Participant-level distribution of select biomarker scores by response status and treatment arm. | Nature Medicine

Fig. 3: Participant-level distribution of select biomarker scores by response status and treatment arm.

From: Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

Fig. 3

a, TcellinfGEP (pembrolizumab plus axitinib, n = 369; sunitinib, n = 361). b, Angiogenesis signature (pembrolizumab plus axitinib, n = 369; sunitinib, n = 361). c, PD-L1 CPS (pembrolizumab plus axitinib, n = 407; sunitinib, n = 409). The center line corresponds to the median, and the box is delineated by the first and third quartiles. Whiskers extend to any points within 1.5 times the interquartile range, with points lying beyond identified individually as potential outliers. P values are nominal (one-sided for pembrolizumab plus axitinib and two-sided for sunitinib) and were derived using a logistic regression model, with adjustment for IMDC risk category. Significance was prespecified at α = 0.05.

Back to article page